Department of Pediatrics, University of Minnesota, Minneapolis, MN 55110,USA.
Pediatr Pulmonol. 2010 Aug;45(8):782-8. doi: 10.1002/ppul.21252.
To determine the effectiveness of artificial surfactant therapy using KL-4 surfactant in newborn pigs with hydrochloric acid (HCl)-induced acute lung injury (ALI).
After induction of ALI via intratracheal HCl instillation, pigs were randomized to receive 5.8 ml/kg KL-4 surfactant or no surfactant prior to extubation to bubble CPAP.
Clinical laboratory.
Spontaneously breathing newborn pigs (<1 week of age).
Treatment with KL-4 surfactant on bubble CPAP with PEEP of 6 cmH(2)O for 3.5 hr after extubation compared with controls.
Physiologic parameters and arterial blood gases were measured every 15 min. At the conclusion of the study, the lungs were excised for the analysis of histopathology and morphometric data.
Pigs treated with KL-4 surfactant had arterial blood gases with less acidosis (P < 0.001), higher P(a)O(2) levels (P < 0.001), and lower P(a)CO(2) levels (P < 0.001). Pigs treated with KL-4 surfactant had improved survival compared with controls (6/12 KL-4, 2/12 control, P < 0.05). Postmortem morphometric data demonstrated that pigs treated with KL-4 surfactant had larger (P < 0.05) exchange units in the caudal-dorsal lung as compared to relatively atelectatic region in the control animals.
In newborn pigs with severe HCl-induced ALI, treatment with KL-4 surfactant resulted in improved respiratory parameters, less dependent atelectasis, and improved short-term survival.
确定使用 KL-4 表面活性剂治疗盐酸(HCl)诱导的新生猪急性肺损伤(ALI)的效果。
通过气管内 HCl 滴注诱导 ALI 后,将猪随机分为接受 5.8 ml/kg KL-4 表面活性剂或在拔管前不接受表面活性剂治疗,然后接受 CPAP 通气。
临床实验室。
自主呼吸的新生猪(<1 周龄)。
与对照组相比,在拔管后接受 KL-4 表面活性剂治疗,在 CPAP 通气时使用 PEEP 为 6 cmH2O,持续 3.5 小时。
每隔 15 分钟测量生理参数和动脉血气。研究结束时,切除肺脏进行组织病理学和形态计量学数据分析。
接受 KL-4 表面活性剂治疗的猪的动脉血气具有更低的酸中毒程度(P<0.001)、更高的 P(a)O2 水平(P<0.001)和更低的 P(a)CO2 水平(P<0.001)。与对照组相比,接受 KL-4 表面活性剂治疗的猪的存活率更高(6/12 KL-4,2/12 对照组,P<0.05)。尸检形态计量学数据表明,与对照组中相对肺不张的区域相比,接受 KL-4 表面活性剂治疗的猪的尾-背侧肺具有更大的(P<0.05)交换单位。
在严重 HCl 诱导的新生猪 ALI 中,KL-4 表面活性剂治疗可改善呼吸参数、减轻依赖性肺不张,并提高短期生存率。